S90 Diabetes Care Volume 38, Supplement 1, January 2015

Index

A1C. see also glycemic targets cardiovascular disease changes, initiatives, S6 CGM, S34 A1C relationship to, S36 demographic changes, S5 children and adolescents, S35, S71 autonomic neuropathy, S25, S62–S63 improvement strategies, S5 glycemic target determination, S37 children and adolescents, S72 patient-centeredness, S5 goals, S35 dietary fat management, S23–S24 regime reevaluation, S6–S7 limitations, S34–S35 patient-centeredness, S5 resources, S6 macrovascular complications, S36 pharmacological therapy, S51–S55, S59 clonidine, S78 mean glucose levels, S35 postprandial plasma glucose testing, S37 clopidogrel, S54, S55 microvascular complications, S35–S36 revisions summary, S4 cognitive impairment, S19, S38, S70 race/ethnicity differences, S9, S35 risk calculator, S52 colesevelam, S42, S44 recommendations, S34, S35, S37 risk factors, S10, S12, S25, S32 comorbidities, S17–S19, S26 SMBG, S33–S34 risk management, S49–S55 congestive heart failure, S51, S55 testing, S8–S10, S12, S34–S35 screening, S31, S55 consensus reports, S1 acarbose, S44 testing frequency, S9 continuous glucose monitoring (CGM), S4, ACCORD trial, S19, S36, S38, S50, S53 Care of Young Children With Diabetes in the S33, S34 A1C Derived Average Glucose (ADAG) trial, Child Care Setting,S86 continuous subcutaneous insulin infusion S35, S37 celiac disease, S71 (CSII), S83 ACE inhibitors, S49–S51, S55, S58–S60, Charcot foot, S64 contraception, S79 S72, S78 children and adolescents coronary heart disease, S55 acute coronary syndrome, S54, S55 A1C goals, S35, S71 cystic fibrosis–related diabetes, S15 adolescents. see children and autoimmune conditions, S71 adolescents cardiovascular disease, S72 dapagliflozin, S45 ADVANCE-BP trial, S50, S51 celiac disease, S71 Da Qing study, S31 ADVANCE trial, S36, S38 cognitive impairment, S70 DAWN2 study, S26 advocacy, S5, S86–S87 DSME/DSMS, S73 day care, S73, S86–S87 African Americans, S9, S11, S12, S24, S35 dyslipidemia, S72 degludec, S45 age. see older adults family stresses, S74 depression, S18, S26, S67, S74 AIM-HIGH trial, S53 glycemic control, S70–S71 detemir, S45 albiglutide, S45 hypertension, S71–S72 Diabetes and Driving, S86 albuminuria, S25, S58–S60, S73 hypoglycemia, S70 Diabetes and Employment, S86 alcohol, S23, S51 nephropathy, S72–S73 Diabetes Care in the School and Day Care alogliptin, S44 neuropathy, S73 Setting, S86–S87 amlodipine, S51 pediatric to adult care transition, Diabetes Control and Complications Trial amputations, S63–S64 S73–S74 (DCCT), S35, S36, S38, S41, S70 amylin mimetics, S45 plasma blood glucose goals, S71 Diabetes Management in Correctional anemia, S9 psychosocial issues, S74 Institutions, S87 angiotensin receptor blockers (ARBs), resources, S86 Diabetes Prevention Program (DPP), S49–S51, S55, S58–S60, S72, S78 retinopathy, S73 S31, S32 ankle-brachial index (ABI), S63, S64 revisions summary, S4 Diabetes Prevention Program Outcomes antihypertensive medications, S51, school, child care, S73 Study (DPPOS), S31, S32 S59, S78 smoking, S72 diabetes-related distress, S26 antiplatelet agents, S54–S55, S61 statins, S72 diabetes self-management education Antithrombotic Trialists’ (ATT) Collaboration, S54 thyroid disease, S71 (DSME) Asian Americans, S9–S12 type 1 diabetes, S10–S11, S70–S74 benefits, S6, S20–S21 aspart, S43, S45 type 2 diabetes, S12–S13, S74 carbohydrate management, S21–S23 aspirin resistance, S55 chlorthalidone, S51 children and adolescents, S73 aspirin therapy, S54–S55, S61 cholesterol. see also dyslipidemia dietary fat management, S23–S24 assisted living. see hospital care children and adolescents, S72 eating patterns, S21–S23 autoimmune disease, S10–S11 control, S51 herbal supplements, S23 Automation to Simulate Pancreatic Insulin monitoring, S53 hospital care, S84 Response (ASPIRE) trial, S34 screening, S10, S52 medical nutrition therapy, S21–S23, S52, autonomic neuropathy, S25, S62–S63 treatment, S52, S55 S72, S83 Chronic Care Model (CCM), S5, S6 micronutrients, S23 bariatric surgery, S46–S47 chronic kidney disease, S23, S25, S58–S60 national standards, S21 benazepril, S51 classification, diagnosis overview, S17, S20–S21 biguanides, S31, S32, S42–S44 overview, S8 prediabetes, S32 bile acid sequestrants, S42, S44, S53 prediabetes, S9–S10, S12–S13 protein management, S22, S23, S59 b-blockers, S51, S55 revisions summary, S4 recommendations, S20, S31 blood pressure control. see hypertension testing, S8–S10 reimbursement, S21 body mass index (BMI), S12 testing frequency, S9 sodium, S23, S24, S51 bromocriptine, S42, S45 claudication, S63 weight loss, S21, S55

INDEX clinical management diabetes self-management support (DSMS). calcium channel blockers, S51, S59 advocacy, S5, S86–S87 see diabetes self-management education canagliflozin, S45 behavior change support, S6 (DSME) cancer, S18 behavior optimization, S6 Diabetic Retinopathy Study (DRS), S61 carbohydrates, S21–S23 care delivery systems, S6 diastolic blood pressure goals, S4 care.diabetesjournals.org Index S91

diet, nutrition, S21–S23 postpartum care, S79 diastolic blood pressure, S50–S51 diltiazem, S78 recommendations, S13 goals, S49, S50 dipeptidyl peptidase 4 (DPP-4) inhibitors, screening, S10 lifestyle modification, S49, S51 S42–S44, S46, S68 two-step strategy, S13–S14 older adults, S67 disordered eating, S74 glargine, S45 overview, S49–S50 diuretics, S49–S51, S58, S59, S78 gliclazide, S44 pharmacological therapy, S49–S51 dopamine-2 agonists, S45 glimepiride, S44 recommendations, S49 driving, S86 glipizide, S44 screening, S10, S49, S50 dulaglutide, S45 glucagon, S38 sodium guidelines, S24, S51 dyslipidemia. see also cholesterol; glucagon-like peptide 1 (GLP-1) agonists, S42, systolic blood pressure, S50, S59 triglycerides S43, S45, S46, S68, S82 treatment, S49, S50 children and adolescents, S72 a-glucosidase inhibitors, S42, S44 Hypertension Optimal Treatment (HOT) trial, S50 control, S51 glulisine, S43, S45 hypertriglyceridemia, S53 lifestyle modification, S52, S55 glyburide/glibenclamide, S44 hypoglycemia monitoring recommendations, S4, S53 glycemic targets. see also A1C A1C goals, S35, S37 recommendations, S51–S52 A1C/microvascular complications CGM, S34 screening, S51 relationships, S35–S36 children and adolescents, S70 treatment, S52–S55 determination, S37 exercise, S25 glycemic control assessment, S33–S35 hospital care, S80–S82 Early Treatment Diabetic Retinopathy Study hospital care, S80–S82 nocturnal, S34 (ETDRS), S61 intercurrent illness, S39 older adults, S68 eating abnormalities, S74 mean glucose levels, S35 overview, S38 eating patterns, S21–S23 mortality findings, S36 pregnancy, S78 e-cigarettes, S4, S25 older adults, S68 prevention, S38, S82 empagliflozin, S45 pregnancy, S77, S78 recommendations, S38 employment, S86 recommendations, S33, S36–S37 treatment, S38 end-stage renal disease (ESRD), S59 revisions summary, S4 hypoglycemia unawareness Epidemiology of Diabetes Interventions and glycemic treatment approaches CGM, S33, S34 Complications (EDIC) study, S35–S36, S38 bariatric surgery, S46–S47 children and adolescents, S70 erectile dysfunction, S63 pharmacological therapy, S41–S46 effects, characterization, S38 exenatide/exenatide ER, S45, S82 revisions summary, S4 recommendations, S38 exercise gram-positive cocci, S64 albuminuria, S25 immune-mediated diabetes, S10–S11 autonomic neuropathy, S25, S62–S63 hearing impairment, S19 immunization recommendations, S4, benefits, S24 hemoglobinopathies, S9 S26–S27 children, S24 hepatitis B vaccination, S26 impaired fasting glucose (IFG), S10, S31 frequency, type, S24 herbal supplements, S23 impaired glucose tolerance (IGT), S10, S31 glycemic control, S24 hospital care incretin-based therapies, S42 hyperglycemia, S25 bedside blood glucose monitoring, S83 indapamide, S50, S51 hypoglycemia, S25 critically ill patients, S80, S81 infections, S64 kidney disease, S23, S25, S58–S60, discharge planning, S80, S83 influenza vaccine, S26–S27 S72–S73 DSME, S84 insulin peripheral neuropathy, S25, S62–S63 glucose abnormalities definitions, S81 basal–bolus, S43, S45, S46, S70, prediabetes, S24 glycemic targets, S80–S82 S71, S82 pre-exercise evaluation, S24–S25 hyperglycemia, S80–S81 combination therapy, S42 recommendations, S24 hypoglycemia, S80–S82 glycemic targets, S38 retinopathy, S25, S60–S62, S73 insulin therapy, S80–S82 hospital care, S80–S82 ezetimibe, S53 management team, S82 hypoglycemia treatment, S38 medical nutrition therapy, S83 intensive insulin regimens, S34 fasting plasma glucose testing, S9 medication reconciliation, S83 MDI, S41 fatty liver disease, S18 non critically ill patients, S80–S82 older adults, S68 fenofibrate, S53 recommendations, S80 pregnancy, S78 fibrates, S53 self-management, S82–S83 recommendations, S33 Finnish Diabetes Prevention Study (DPS), S31 sliding scale insulin (SSI), S80, S82 sliding scale insulin (SSI), S80, S82 foot care, S4, S63–S64 structured discharge communication, S83 type 1 diabetes, S41 foot infections, S64 type 1 diabetes, S82 type 2 diabetes, S42–S46 foundations of care revisions summary, S4 hydrochlorothiazide, S51 insulin dependent diabetes, S10–S11 fractures, S18–S19 hyperglycemia insulin pump therapy, S33, S41, S43, S83 FRAX score, S18 cognitive impairment, S19 insulin resistance, S10, S78 fundus photographs, S61 exercise, S25 insulin secretagogues, S38, S68 glycemic target determination, S37 International Association of the Diabetes gastrointestinal neuropathies, S62 hospital care, S80–S81 and Pregnancy Study Groups gastroparesis, S63 older adults, S67, S68 (IADPSG), S13 genitourinary tract disturbances, S62–S63 plasma glucose testing, S9 gestational diabetes mellitus (GDM). see also postprandial, S37 jail, S87 pregnancy risk factors, S11 juvenile-onset diabetes, S10–S11 classification, S8 Hyperglycemia and Adverse Pregnancy diagnosis, S13–S14 Outcome (HAPO) study, S13 kidney disease, S23, S25, S58–S60, S72–S73 glycemic targets, S77, S78 hyperglycemic crisis, S9 Kumamoto Study, S36 management, S78 hypertension one-step strategy, S13, S14 children and adolescents, S71–S72 labetalol, S78 overview, S13, S77 diagnosis, S49, S50 lactation, S79 S92 Index Diabetes Care Volume 38, Supplement 1, January 2015

laser photocoagulation therapy, S61–S62 hypoglycemia, S68 repaglinide, S44 lifestyle modifications pharmacological therapy, S68–S69 retinal photography, S61 dyslipidemia, S52, S55 recommendations, S67 retinopathy, S25, S60–S62, S73 hypertension, S49, S51 sodium guidelines, S24 revisions summary, S4 type 2 diabetes, S31, S42 statin therapy, S52, S53 Reye syndrome, S54 linagliptin, S44 treatment goals, S67–S68 risk management, S4, S6, S9, S11 liraglutide, S45 type 2 diabetes screening, S12 rosiglitazone, S44 lispro, S43, S45 orthostatic hypotension, S63 lixisenatide, S45 overweight, obesity, S9, S10, S21, S55, SAVOR-TIMI 53 trial, S68–S69 Look AHEAD trial, S18, S55 S78–S79 saxagliptin, S44, S68–S69 loss of protective sensation (LOPS), school, S73, S86–S87 S63, S64 Patient-Centered Medical Home, S6 scientific evidence grading, perindopril, S50, S51 S1–S2 macrovascular complications, S35, S36, S51 periodontal disease, S19 scientific statements, S1 macular edema, S61 peripheral arterial disease, S63, S64 self-monitoring of blood glucose management planning, S17–S19, S26 peripheral neuropathy, S25, S62–S63 (SMBG) maturity-onset diabetes of the young pharmacological therapy basal insulin/oral agents, S34 (MODY), S14 cardiovascular disease, S51–S55, S59 intensive insulin regimens, S34 medical evaluation, S17, S18, S24–S25 hypertension, S49–S51 optimization, S33–S34 medical nutrition therapy, S21–S23, S52, S72, microvascular complications, S51 overview, S33 S83 older adults, S68–S69 recommendations, S33 Medicare/Medicaid, S21 prediabetes, S32 sickle cell trait, S9 medications, S12. see also pharmacological type 2 diabetes, S31–S32, S42–S46 sitagliptin, S44, S82 therapy; specific medications, conditions pioglitazone, S44, S46 skilled nursing facilities. see hospital care meglitinides, S42, S44 pneumococcal polysaccharide vaccine 23 sliding scale insulin (SSI), S80, S82 mental health specialist referrals, S26 (PPSV23), S26, S27 smoking, S4, S25, S63, S72 metformin, S31, S32, S42–S44, S55, S59, polycystic ovary syndrome, S10 sodium, S23, S24, S51 S68 position statements, S1 sodium–glucose cotransporter 2 (SGLT2) methyldopa, S78 pramlintide, S41–S42, S45 inhibitors, S42, S43, S45, S46 microvascular complications prasugrel, S55 Standards of Care recommendations, S1 A1C goals, S35 prazosin, S78 Staphylococci, S64 A1C relationship to, S35–S36 prediabetes statins, S4, S52–S55, S72 erectile dysfunction, S63 classification, diagnosis, S9–S10, stroke, S36, S54, S59 gastroparesis, S63 S12–S13 sulfonylureas glycemic control, S63 DSME/DSMS, S32 A1C/CVD relationships, S36 kidney disease, S23, S25, S58–S60, exercise, S24 combination therapy, S42, S43 S72–S73 pharmacological therapy, S32 older adults, S68 neuropathy, S25, S62–S63, S73 pre-exercise medical evaluation, S24–S25 type 2 diabetes, S43, S44, S46 orthostatic hypotension, S63 pregnancy patient education, S64 A1C testing, S9, S78 testosterone levels, S19 pharmacological therapy, S51 antihypertensive medications, S51, thiazolidinediones, S43, S44, S46 retinopathy, S25, S60–S62, S73 S78 thyroid disease, S71 revisions summary, S4 contraception, S79 ticagrelor, S55 risk factors, S11 GDM (see gestational diabetes mellitus triglycerides, S10, S52, S53. see also miglitol, S44 [GDM]) dyslipidemia monogenic diabetes syndromes, S14–S15 glycemic targets, S77, S78 2-hour plasma glucose testing, S9 myocardial infarction (MI), S36, S50, S54, S55, hypertension, S50 type 1 diabetes S59 hypoglycemia, S78 A1C/mean glucose relationship, insulin, S78 S35 nateglinide, S44 insulin resistance, S78 autoimmune conditions, S71 National Diabetes Education Program (NDEP), lactation, S79 carbohydrate management, S21 S6, S74 medications contraindicated, S77, S78 CGM, S33, S34 National Diabetes Prevention Program, S31 metabolic physiology, S78 children and adolescents, S10–S11, National Institutes of Health (NIH), overweight, obesity, S78–S79 S70–S74 S13–S14 postpartum care, S79 classification, S8 neonatal diabetes, S14 preconception counseling, S77 diagnosis, S10–S11 nephropathy, S23, S25, S58–S60, S72–S73 recommendations, S77 glycemic control, neuropathy, S25, S62–S63, S73 retinopathy, S25, S60–S62, S73 S70–S71 niacin, S53 revisions summary, S4 hospital care, S82 NICE-SUGAR trial, S81 screening, S10 hypoglycemia, S38 nonproliferative diabetic retinopathy statins, S72 insulin, S41 (NPDR), S61 prison, S87 pharmacological therapy, S41–S42 nursing home. see hospital care Professional Practice Committee, S3, pregnancy, S78–S79 S88–S89 progression estimates, S11 obstructive sleep apnea, S18 proliferative diabetic retinopathy, S61 retinopathy, S25, S60–S62, S73 older adults protein, S22, S23, S59 SMBG, S34 A1C levels, S9 psychosocial screening, care, S25–S26 statin therapy, S53 depression screening, S67 P2Y12 receptor antagonist, S55 testing, S11 diabetes complications screening, S67 type 2 diabetes glycemic targets, S68 race/ethnicity, S9, S12, S35. see also African A1C goals, S35 hyperglycemia, S67, S68 Americans; Asian Americans A1C/macrovascular complications hypertension, S67 RAS inhibitors, S51, S59 relationships, S36 care.diabetesjournals.org Index S93

children and adolescents, S12–S13, overview, S11 UK Prospective Diabetes Study (UKPDS), S74 pharmacological therapy, S31–S32, S36, S59 classification, S8 S42–S46 ulcers, S63–S64 combination therapy, S42, S43 pregnancy, S78–S79 community screening, S12 prevention, delay of, vascular endothelial growth factor (VEGF), comorbidities, S74 S31–S32 S61, S62 diagnosis, S11–S13 recommendations, S11, S31 vascular pathology measures, S37 diagnostic tests, S12 retinopathy, S25, S60–S62, S73 Veterans Affairs Diabetes Trial (VADT), S36 hypoglycemia, S38 risk factors, S11–S12 vildagliptin, S44 ketoacidosis, S11 screening, S12, S31 lifestyle modifications, S31, S42 testing interval, S12 weight loss, S21, S55